Citations

Clear

100 citation(s) found for "Shukla, R".

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles
Fleur-Lominy, Shella Saint , Sun, Zhuoxin , Shukla, Mihir, Fernández, Hugo F. , Foran, James M. , Cripe, Larry D., Wiernik, Peter H. , Rowe, Jacob M. , Tallman, Martin S. , Litzow, Mark R. , Zhang, Yanming , Luger, Selina M. , Chen, Li , Garrett-Bakelman, Francine E. , Lazarus, Hillard M. , Khan, Irum

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 290-290

10.1182/blood-2025-290 Get It

Abstract Background: Population registries and the Alliance co-operative group database have highlighted racial disparities in AML survival attributed to differential prevalence and impact of oncogenic drivers on disease biology. However, the small number of Black patients with well-annotated genomic profiles limits the validity of these findings. The current study leverages ECOG-ACRIN cytogenetic and outcomes data from newly diagnosed adult AML patients treated on intensive chemotherapy-based clinical trials over three decades. Methods: Self-reported race was categorized as White, Black or Other. Descriptive statistics were used to summarize baseline characteristics using the Wilcoxon rank-sum and Fisher's exact tests. Multivariable Cox proportional hazards regression models evaluated the association between race and survival outcomes adjusting for age, hemoglobin, platelet count, white blood cell count, blast percentage, performance status and ELN cytogenetic risk score (RS). All Cox models were stratified by protocol. Subgroup analyses of overall survival (OS) and disease-free survival (DFS) were performed using Kaplan-Meier curves stratified by race using log-rank tests. All statistical tests were two-sided. Analyses included only patients with complete data for the variables of interest. Results: Data was collected across 10 phase II and III interventional trials for newly diagnosed adult AML that accrued patients between 1984 and 2019. The study population included 3469 White, 184 Black, and 156 Other patients with a Black representation of 1.1-11% across trials. Blacks were significantly younger at diagnosis with a median age of 47.9 years compared to 53.5 years in Whites (p<0.001). Racial groups were well matched for gender and performance status. Black race was an independent prognostic factor for inferior OS (HR 1.212, CI 1.01 – 1.453; p = 0.0383) and DFS (HR 1.313, CI 1.05-1.641; p = 0.017). Complete cytogenetic results were available for 117 Black and 2162 White patients and revealed no significant racial differences in the distribution of ELN 2017 cytogenetic RS, although core binding factor AML was non-significantly enriched in Black patients (12.8% vs 8.3%). No difference was observed between Blacks and Whites in the prevalence of complex karyotype (CK), CK with -5/del(5q), -7/del(7q), or -17/del(17p), and AML-MRC including +8 and del(20q). Notably, the ELN 2017 cytogenetic RS effectively predicted OS in Black (57.8 vs 14.2 vs 5.8 months in favorable, intermediate and adverse RS, p = 0.018), and White patients (60.1 vs 15.2 vs 7.1 months, p < 0.0004 for Whites) but only predicted DFS for White AML patients (p < 0.0001 for Whites, p=0.48 for Blacks). In patients with molecular data for FLT3-ITD (n=1218), CEBPA (n=576), TP53 (n=572), or NPM1(n=683), no racial difference in the prevalence of these mutations was observed. However, NPM1 mutations were associated with inferior OS in Blacks compared to Whites (19.1 vs 8.9 months; p = 0.0095). Black and White AML patients had similar responses with complete remission rates of 58.2% vs 57.5%, p=0.55, and treatment tolerability with 30-day mortality of 7.1% vs 8.9%, p=0.50. However, consolidation approaches differed significantly. Among patients that underwent stem cell transplant (SCT), a significantly higher percentage of White patients received allogenic SCT compared to Blacks (48.5% versus 37.1%, p <0.01). Conclusions: This study represents one of the largest race-based comparisons of cytogenetic abnormalities and clinical outcomes in prospective trials of intensive chemotherapy in AML . Our data confirms the independent prognostic relevance of race in AML survival and validates the predictive ability of the ELN 2017 cytogenetic RS for OS across racial groups. There is ancestry-based attenuation of the survival benefit of NPM1 mutations as previously reported, underscoring the need to tailor the current treatment approach to NPM1 mutated AML based on race. The availability of NGS data limited the genomic analysis to a subset of patients. Future studies should examine the depth of treatment response incorporating MRD biomarkers and explore the effect of race on co-occurring mutations and the leukemic stem cell transcriptome to better explain the observed disparities. Finally, persistent disparities in access to allo-SCT even within the context of clinical trials reinforces the need to address diversity in the stem cell donor pool and social barriers to transplant.
From abstract to article: publication rates of abstracts presented at the Society for Healthcare Epidemiology of America spring conference 2018 and 2021
Rajani, Aayushi J. , Karatela, Shifa , Modha, Lipi, Bhuptani, Hitanshi, Shah, Purav , Shukla, Anand , Amin, Juhi , Gandhi, Devisha, Chitale, Rohit , Durvasula, Ravi, Oring, Justin , Rajani, Aayushi J , Shukla, Abhijeet , Karatela, Shifa , Chitale, Rohit A , Gandhi, Devisha

Mayo Clinic

Infection Control & Hospital Epidemiology | November 21, 2025 | Volume: 47 | Issue: 1 | Pages: 88-90

10.1017/ice.2025.10348 | PMID 41267527 Get It

Abstract The publication rate of abstracts presented at a conference can provide some insight into its academic quality, although it is hardly the sole metric. We evaluated 351 SHEA Spring Conference abstracts; 49.9% were published. Findings demonstrate the strong academic output of SHEA conferences.
Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis
Abrams, Aaron , Waltz, Michael , Casper, T. Charles , Aaen, Gregory , Bernfeld, Eva‐Chava M., Charvet, Leigh , Francisco, Carla , Gorman, Mark , Lotze, Timothy E. , Mar, Soe , Ness, Jayne , Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Wheeler, Yolanda , Abrams, Aaron , Charvet, Leigh E , Krupp, Lauren , O'Neill, Kimberly , Waubant, Emmanuelle L. , Krysko, Kristen M , Benson, Leslie A., Bernfeld, Eva Chava, Chitnis, Tanuja , Graves, Jennifer , Rensel, Mary R. , Rodriguez, Moses , Rutatangwa, Alice , Schreiner, Teri , Shukla, Nikita , Weinstock‐Guttman, Bianca , Krysko, Kristen M.

Mayo Clinic

Annals of Neurology | November 6, 2025 | Volume: 99 | Issue: 3 | Pages: 715-729

10.1002/ana.78086 | PMID 41195640 Get It

Objective To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. Results A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety‐three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52–1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20–0.57; rate ratio: 0.38, 95% CI = 0.21–0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09–0.37; rate ratio: 0.21, 95% CI = 0.10–0.44) ( p < 0.001). Adjusted number needed to treat in person‐years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03–8.69) and infusion over injectable 1.43 (95% CI = 1.00–3.88). Interpretation Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long‐term safety data are required. ANN NEUROL 2026;99:715–729
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry
Wright, Melissa A. , Barney, Bradley J. , Peterson, Skyler, Waltz, Michael , Rose, John W. , Rensel, Mary , Abrams, Aaron , Waubant, Emmanuelle , Wheeler, Yolanda , Rodriguez, Moses , Tillema, Jan-Mendelt , Gorman, Mark , Lotze, Timothy E. , Mar, Soe , Schreiner, Teri , Vignos, Megan , Casper, T. Charles , Rose, John W , Krupp, Lauren , Gorman, Mark P , Benson, Leslie A , Lotze, Timothy E , Shukla, Nikita Malani , Mar, Soe S , Chitnis, Tanuja , Schreiner, Teri , Vignos, Megan , Rensel, Mary R. , Waubant, Emmanuelle L. , Rodriguez, Moses , Waltz, Michael , Wright, Melissa A , Tillema, Jan‐Mendelt , Benson, Leslie , Shukla, Nikita

Mayo Clinic

Journal of Child Neurology | September 16, 2025 | Volume: 41 | Issue: 4 | Pages: 545-555

10.1177/08830738251367460 | PMID 40956912 Get It

This study evaluated the efficacy of the multiple sclerosis disease-modifying therapies, intramuscular interferon beta-1a (Avonex) and subcutaneous peginterferon beta-1a (Plegridy), using data from the United States Network of Pediatric Multiple Sclerosis Centers. In this retrospective analysis, 154 patients with multiple sclerosis were included who were treated with Avonex (n = 130), Plegridy (n = 23), or both treatments (n = 1) before the age of 18 years. After 3 months’ sustained use acclimation (“wash-in”), the probability of being relapse-free during the first year was 68.3% for Avonex-treated patients and 69.9% for Plegridy-treated patients; annualized relapse rates were 0.50 and 0.59, respectively. Both disease-modifying therapies demonstrated efficacy similar to that reported in adult populations. Despite the lack of formal approval for pediatric multiple sclerosis, these outcomes indicate that patients may benefit from treatment with Avonex or Plegridy. Understanding efficacy of specific disease-modifying therapies in pediatric multiple sclerosis is essential to making informed treatment decisions.
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Epstein‐Peterson, Zachary D. , Lionel, Anath C. , Joseph, Ashlee , Drill, Esther , Atallah‐Yunes, Suheil Albert , Brooks, Taylor , Chong, Elise A. , Chong, Emeline R. , Cruz, Jamie Dela , Frank, Matthew J. , Jacobson, Caron A. , Beyar‐Katz, Ofrat , Maddocks, Kami J. , McLoughlin, Daniel E. , Navalekar, Rohin, Ryan, Christine E. , Sauter, Craig S. , Sharma, Samanvaya , Shukla, Navika , Therwhanger, Dylan , Besien, Herman J. van, Varon, Ben , Yamshon, Samuel , Palomba, M. Lia , Kumar, Anita , Brooks, Taylor R , Kamdar, Manali , Karmali, Reem , Matasar, Matthew , McLoughlin, Daniel , Rhodes, Joanna , Riedell, Peter A , Ryan, Christine E , Salles, Gilles A , Sawalha, Yazeed , Sharma, Samanvaya , Shouval, Roni , Therwhanger, Dylan , van Besien, Herman , Varon, Ben , Wang, Yucai , Yamshon, Samuel , Zelenetz, Andrew D , Jain, Preetesh , Kumar, Anita , Chong, Elise A , Joseph, Ashlee , Atallah-Yunes, Albert , Ip, Andrew , Iqbal, Madiha , Kamdar, Manali , Karmali, Reem , Matasar, Matthew J. , Merryman, Reid W. , Muñoz, Javier , Navalekar, Rohini, Rhodes, Joanna , Riedell, Peter A. , Salles, Gilles , Sawalha, Yazeed , Wang, Yucai , Zelenetz, Andrew D. , Jain, Preetesh

Mayo Clinic

Blood Advances | August 5, 2025 | Volume: 9 | Issue: 21 | Pages: 5654-5662

10.1182/bloodadvances.2025016315 | PMID 40763269 Get It

Abstract The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post–CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (&lt;3 vs 3-6 vs &gt;6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R/R MCL, and establish a benchmark for future investigations in this patient population.
P31 Improvement in health-related quality of life in moderate to severe Crohn’s disease patients treated with risankizumab versus ustekinumab: SEQUENCE study
Sands, Bruce E, Blumenstein, Irina , Joshi, Namita , Kligys, Kristina, Anschutz, Toni , Griffith, Jenny, Zambrano, Javier , Louis, Édouard , Loftus, Edward V. , Jairath, Vipul , Shukla, Nidhi , Louis, Edouard

Mayo Clinic

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A110.1-A110

10.1136/gutjnl-2025-bsg.168 Get It

P22 Economic impact of risankizumab induction therapy on UC-related hospitalisations and work productivity: data from the phase 3 induction study
Dulai, Parambir S. , Cross, Raymond, Parkes, Gareth , Shukla, Nidhi, Levine, Phillip, Hecht, Patrick , González, Yuri Sánchez , Sharma, Dolly, Loftus, Edward V. , Dignass, Axel , Lai, Jyun‐Heng , Siegel, Corey A

Mayo Clinic

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A104-A104

10.1136/gutjnl-2025-bsg.159 Get It

Evaluating artificial intelligence (AI) as a clinical decision support tool for lung cancer treatment recommendations.
Odabashian, Roupen, Karson, Jeffrey A. , Shukla, Asmita, Reddy, Sushmitha Nanja, Yalavarthi, Nagasai, Muthu, Padmapriya , Soni, Suha , Desai, Aakash , Desai, Aakash P , Odabashian, Roupen , Karson, Jeffrey, Dyson, Gregory , Hadid, Tarik H. , Manochakian, Rami , Dimou, Anastasios , Mamdani, Hirva Mansurali

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e20011 Get It

e20011 Background: The therapeutic landscape of lung cancer is rapidly evolving, presenting oncologists with the challenge of staying updated amidst an overwhelming influx of data. Clinical decision support (CDS) tools, including artificial intelligence (AI) and large language models (LLMs), may help bridge this gap. Evaluating the accuracy of LLMs in complex, real-world oncology scenarios is crucial to understanding their potential. Methods: Twenty-five de-identified lung cancer cases from the fellows’ clinic at Karmanos Cancer Institute, Detroit, MI, were analyzed. Two LLMs, GPT-4 (OpenAI) and Claude Opus (Anthropic), were assessed using advanced prompting techniques like persona-based and chain-of-thought prompting. Five board-certified lung cancer oncologists from NCI-designated centers evaluated LLM-generated responses based on accuracy, treatment recommendation comprehensiveness, and supportive care planning, using a 1–5 scale. Novel insights, the presence of fabricated information, and harmful recommendations were flagged as binary outcomes. Oncologists were blinded to the LLM source and actual treatment decisions. Results: Table 1 presents patient characteristics. GPT-4 achieved an average accuracy score of 4.2 (95% CI, 3.9–4.4), with 3.7 for comprehensiveness of medical/surgical treatment recommendations and 3.7 for supportive care planning. Six responses (32%) were flagged as potentially harmful, and two (8%) contained inaccuracies. Sixteen GPT-4 responses (64%) were rated trustworthy as a CDS tool. Claude Opus had an average accuracy score of 3.6 (95% CI, 3.1–4.1), scoring 3.6 for treatment recommendation comprehensiveness and 3.5 for supportive care planning. Nine responses (36%) were flagged for potential harm, and five (20%) included inaccuracies. Eleven Claude responses (44%) were deemed trustworthy. Significant differences were observed in accuracy (p=0.04) and trustworthiness (p=0.03) between models using McNemar's test. Other factors showed no statistical significance. Conclusions: GPT-4 outperformed Claude Opus in accuracy and trustworthiness, but both models demonstrated limitations, including harmful recommendations and inaccuracies. These findings highlight the need for improved LLM refinement before routine use as CDS tools in lung cancer treatment. Patient demographics and clinical characteristics. Category subcategory Number Median Age (range)- Yr 65 (26-78) Female 7 Male 18 Histology Adenocarcinoma 10 Squamous Cell Carcinoma (SCC) 7 Small Cell Carcinoma 6 Poorly Differentiated 2 Total 25 Stage NSCLC Stage 3 7 NSCLC Stage 4 13 Small Cell limited stage 3 Small Cell Extensive Stage 2
A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s disease
Johnson, Amanda M. , Askar, Manar, Belani, Seema, Xu, Anthony , Kassmeyer, Blake , Said, Hyder , Santiago-Castro, Michael, Devi, Jalpa , Huang, Katherine , Jaiprada, Fnu, Seth, Nickhil, Dulaney, David , Fenster, Marc, Shukla, Richa, Yarur, Andrés , Santiago-Castro, Michael , Devi, Jalpa , Bishu, Shrinivas , Ungaro, Ryan , Deepak, Parakkal , Yarur, Andres J , Khan, Abdul Wali , Seth, Nickhil, Loftus, Edward V. , Patel, Anish A , Bishu, Shrinivas , Ungaro, Ryan C. , Shukla, Richa, Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | April 18, 2025 | Volume: 19 | Issue: 5 | Pages: No page available

10.1093/ecco-jcc/jjaf070 | PMID 40289770 Get It

Abstract Background We aimed to evaluate the effectiveness and safety of risankizumab (RZB) for Crohn’s disease (CD) in routine clinical practice. Methods We performed a retrospective review of a multicenter consortium of CD patients treated with RZB. Co-primary outcomes were week 12 clinical remission (Harvey Bradshaw Index [HBI] score of ≤4 or physician global assessment in those without HBI or with ileostomy) and 6-month endoscopic remission (Simplified Endoscopic Mucosal Assessment for Crohn’s Disease of 0-1 or absence of ulcers). Secondary outcomes included steroid-free clinical remission, clinical response, radiographic response, cumulative clinical and endoscopic remission rates at 6 and 12 months, and adverse events. Results A total of 309 patients were included (median disease duration 14 years [IQR, 6-24]; median follow-up 7.1 months [IQR, 4.1-10.3]). Most patients (85.8%) were advanced therapy (AT)-exposed, and 169 (54.7%) had prior ustekinumab (UST) exposure. Week 12 clinical remission rates were 49.7% (98/197) overall, and 44.2% (50/113) vs 57.1% (48/84) in UST-exposed vs naïve patients (P = .073). Among those with active disease on baseline endoscopy (n = 122) who had an available follow-up at 6 months, 52.4% (22/42) achieved endoscopic remission. Cumulative rates of clinical and endoscopic remission at 12 months were 65.0% and 49.5%, respectively. Cumulative 12-month endoscopic remission was 33.9% (19/56) in UST-exposed and 68.1% (32/47) in UST-naïve patients (P &lt; .001). Risankizumab was well-tolerated with no new safety signals identified. Conclusions In this large multicenter cohort of patients with CD, RZB was well-tolerated and effective in achieving favorable clinical and endoscopic outcomes in both AT-exposed and naïve populations, including those with exposure to UST.
Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus
Cohen, Elisabeth J. , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Warner, David B., Lu, Ying , Twi-Yeboah, Alberta , Kim, Jiyu , Lopez-Jimenez, Carlos, Laury, Sarah, Jeng, Bennie H., Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Keenan, Jeremy, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Sugar, Alan , Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Harris, David J. , Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad Fitri , Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, María José , Barron, Bruce J., Hindman, Holly B. , Wise, R., Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, Ann M, Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John E., Ingraham, Herbert J., Guibord, Nathalie M., Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., FORSTOT, S. LANCE, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Ashe, S, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, M. Christopher , Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Robert, Marie‐Claude , Rullo, Jacob, Johnson, Davin , Mah, Dean, Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly , Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Meyer, Jay J. , Niederer, Rachael L. , Colby, Kathryn , McLeod, Stephen D. , Melia, Michele , Sugar, Elizabeth A. , Taylor, Carol R., Nagel, Maria A. , Lass, Jonathan H. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Warner, David B., Lu, Ying, Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Hamrah, Pedram , Lee, Hyunjoo, Weikert, Mitchell P. , Hood, Christopher T. , Woodward, Maria A. , Shtein, Roni Mintz , Zaffos, Joshua, Prescott, Christina R. , Haberman, Ilyse D. , Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Amir, Ahmad, Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Barron, Bruce, Wise, Ronald, Shieh, Christine , Thorne, George, Renucci, A., Sivaraman, Kavitha, Affeldt, John, Guibord, Nathalie M, Lin, Amy , Patel, Ravi, Asbell, Penny A. , Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Yung, C.–W., Lin, Charles C. , Vyas, Neil M, Oates, Dale, Veena, Mathew, Goshe, Jeffrey M. , Sharma, Vikas , Miller, Darby D. , Ma, Jeffrey H, Dupps, William Joseph

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 269

10.1001/jamaophthalmol.2024.6114 | PMID 40048183 Get It

Importance High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. Objective To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point). Design, Setting, and Participants The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024. Immunocompetent, nonpregnant adults with a history of an HZO rash, documented active keratitis or iritis within 1 year, and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater were eligible. After determined to be eligible, participants were randomized in 4 strata: age at onset (&amp;lt;60 years vs ≥60 years) and disease duration (&amp;lt;6 months vs ≥6 months). Interventions A total of 12 months of double-masked daily valacyclovir, 1000 mg, or placebo. Main Outcomes and Measures The primary outcome was time to first occurrence within 12 months of new or worsening SK, EK, iritis, or DEK. Results A total of 527 participants (median [IQR] age, 60 [50-68] years; 266 female [50.5%]; 266 in the valacyclovir group; 261 in the placebo group) were randomized in 4 strata; 481 completed 12 months, and 460 completed 18 months. Data were analyzed by intention to treat. At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. The hazard ratio (HR) of the primary end point at 12 months was 0.77 for participants taking valacyclovir vs placebo (HR, 0.77; adjusted 95% CI, 0.56-1.05; P = .09) and 0.73 at the secondary end point at 18 months (HR, 0.73; adjusted 95% CI, 0.55-0.97; P = .03). There was a reduction of multiple other secondary end points at 12 months (HR, 0.70; 95% CI, 0.52-0.95; P = .02) and 18 months (HR, 0.72; 95% CI, 0.55-0.95; P = .02). Conclusions and Relevance Although the primary outcome did not show a benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months. These results support consideration of 1 year of suppressive valacyclovir treatment for HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196